Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.43 |
| ▸ | GNPAT | O15228 | 1/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9561349 | 1.00 | GSR (0.52) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL31078832 | 0.96 | FOLH1 (0.49) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL31078294 | 0.96 | FOLH1 (0.49) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL31078367 | 0.96 | FOLH1 (0.49) | GSRFOLH1DPP8DPP9DPP7 | |
| Bromide SCHEMBL9724138 | 0.96 | FOLH1 (0.49) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL31078257 | 0.96 | FOLH1 (0.49) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL31078152 | 0.96 | FOLH1 (0.49) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL31078326 | 0.96 | FOLH1 (0.49) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL31078174 | 0.96 | FOLH1 (0.49) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL31078270 | 0.96 | FOLH1 (0.49) | GSRFOLH1DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001910-A1 | PEPTIDES AND USES THEREOF | PREVECEUTICAL MEDICAL INC (CA) | 2026-01-01 | — | — | US | claimed |
| US-20260001910-A1 | PEPTIDES AND USES THEREOF | PREVECEUTICAL MEDICAL INC (CA) | 2026-01-01 | — | — | US | disclosed |
| US-20250345492-A1 | AN ANTIBACTERIAL POLYPEPTIDE COMPOUND, A MEDICAL DEVICE, HYDROGEL AND USE THEREOF | GUANGZHOU TOWE BIOTECH CO LTD (CN) | 2025-11-13 | — | — | US | disclosed |
| US-20250332217-A1 | IMMUNE CHECKPOINT INHIBITOR COMBINATIONS | LYTIX BIOPHARMA AS (NO) | 2025-10-30 | — | — | US | disclosed |
| EP-4637799-A1 | MEDICAL PRODUCTS CONTAINING AN AQUEOUS FORMULATION OF A PEPTIDE | Lytix Biopharma AS (NO) | 2025-10-29 | — | — | EP | disclosed |
| US-12239686-B2 | Immune checkpoint inhibitor combinations | LYTIX BIOPHARMA AS (NO) | 2025-03-04 | — | — | US | disclosed |
| US-20250002854-A1 | METHODS OF GENERATING POPULATIONS OF TUMOUR-INFILTRATING T CELLS | VERRICA PHARMACEUTICALS INC. | 2025-01-02 | — | — | US | disclosed |
| CN-118698507-A | Preparation method of phospholipid affinity monolithic column and application of monolithic column | 无锡萃纯生物材料科技有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-118638745-A | Method for purifying lentivirus | 无锡萃纯生物材料科技有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-20240293506-A1 | IMMUNE CHECKPOINT INHIBITOR COMBINATIONS | LYTIX BIOPHARMA AS (NO) | 2024-09-05 | — | — | US | disclosed |
| CN-117362390-A | Polypeptide compound for small nucleic acid drug delivery and application thereof | 陈璞 | 2024-01-09 | — | — | CN | disclosed |
| US-20230201305-A9 | IMMUNE CHECKPOINT INHIBITOR COMBINATIONS | LYTIX BIOPHARMA AS (NO) | 2023-06-29 | — | — | US | disclosed |
| CN-115869459-A | Polypeptide hydrogel for promoting wound healing and preparation method and application thereof | 广州图微科创生物科技有限公司 | 2023-03-31 | — | — | CN | disclosed |
| WO-2022143219-A1 | ANTIBACTERIAL POLYPEPTIDE COMPOUND, MEDICAL INSTRUMENT, HYDROGEL, AND APPLICATION THEREOF | 广州图微科创生物科技有限公司 | 2022-07-07 | — | — | WO | disclosed |
| CN-101868563-B | Base processing agent for metal material and method for processing base for metal material | NIHON PARKERIZING | 2012-09-12 | — | — | CN | disclosed |
| CN-101868563-A | Base processing agent for metal material and method for processing base for metal material | NIHON PARKERIZING | 2010-10-20 | — | — | CN | disclosed |
| EP-0346460-B1 | PURINE DERIVATIVES HAVING PHARMACOLOGICAL ACTION | CO PHARMA CORPORATION (IT) | 1993-03-10 | — | — | EP | disclosed |
| US-5110798-A | Immunomodulators for bone marrow transplants | CO PHARMA CORPORATION S.R.L. (IT) | 1992-05-05 | — | — | US | disclosed |
| EP-0346460-A1 | PURINE DERIVATIVES HAVING PHARMACOLOGICAL ACTION. | CO PHARMA CORP SRL (IT) | 1989-12-20 | — | — | EP | disclosed |
| WO-1989005818-A1 | PURINE DERIVATIVES HAVING PHARMACOLOGICAL ACTION | CO PHARMA CORPORATION S.R.L. (IT) | 1989-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002854-A1 | METHODS OF GENERATING POPULATIONS OF TUMOUR-INFILTRATING T CELLS | CD4, GZMB, PRF1 | GSR 2388/4885FOLH1 64/4885DPP8 2186/4885 |
| US-20260001910-A1 | PEPTIDES AND USES THEREOF | MMP3, PEPD, MMP9 | GSR 2148/4885FOLH1 88/4885DPP8 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.